Zentiva gains semi-exclusive commercialization rights to Biocon’s liraglutide drug-device combination in 30 countries, following a string of similar deals for the company since its 2018 acquisition.
Biocon has signed a semi-exclusive partnership agreement with Zentiva covering Biocon’s drug-device combination liraglutide. The product treats and manages Type 2 Diabetes and obesity.
The deal will see Biocon manufacture and supply Liraglutide to Zentiva, who will commercialize the drug across 30 countries in...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
